Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant
Launched by ASAN MEDICAL CENTER · Jan 28, 2024
Trial Information
Current as of July 01, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients
- • Underwent liver transplantation for treating hepatocellular carcinoma
- • Between Jan. 2008 - May. 2022
- Exclusion Criteria:
- • Pediatric patients (Age under 18 years)
- • Re-transplantation
- • Multi-organ transplantation
About Asan Medical Center
Asan Medical Center, located in Seoul, South Korea, is a leading healthcare institution renowned for its commitment to advanced medical research and patient care. With a focus on innovative clinical trials, the center aims to enhance healthcare outcomes through rigorous scientific investigation and collaboration. Asan Medical Center is equipped with state-of-the-art facilities and a multidisciplinary team of experts dedicated to exploring new therapeutic approaches across various medical fields. Its robust infrastructure supports a wide range of clinical studies, contributing significantly to the global medical community's understanding of diseases and treatment efficacy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Jun-Gol Song, MD, PhD
Study Chair
Department of Anesthesiology and Pain Medicine, Asan Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported